Simplicity Solutions LLC cut its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 118,301 shares of the company’s stock after selling 93 shares during the quarter. Simplicity Solutions LLC’s holdings in Johnson & Johnson were worth $18,542,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. 4J Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 2.2% in the 4th quarter. 4J Wealth Management LLC now owns 2,835 shares of the company’s stock worth $444,000 after purchasing an additional 62 shares during the period. My Personal CFO LLC raised its stake in Johnson & Johnson by 1.4% during the 4th quarter. My Personal CFO LLC now owns 4,550 shares of the company’s stock worth $713,000 after acquiring an additional 62 shares during the period. Eagle Strategies LLC raised its stake in Johnson & Johnson by 1.8% during the 4th quarter. Eagle Strategies LLC now owns 3,589 shares of the company’s stock worth $563,000 after acquiring an additional 63 shares during the period. FIDELIS iM LLC raised its stake in Johnson & Johnson by 3.1% during the 4th quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock worth $374,000 after acquiring an additional 64 shares during the period. Finally, Clearview Wealth Advisors LLC raised its stake in Johnson & Johnson by 1.5% during the 4th quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock worth $685,000 after acquiring an additional 64 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Johnson & Johnson Trading Up 0.7 %
JNJ stock opened at $145.74 on Friday. The firm has a fifty day moving average price of $156.32 and a 200 day moving average price of $155.68. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The firm has a market cap of $351.20 billion, a PE ratio of 9.09, a price-to-earnings-growth ratio of 2.40 and a beta of 0.53.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The firm had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same period last year, the firm posted $2.68 earnings per share. Johnson & Johnson’s revenue for the quarter was up 2.3% compared to the same quarter last year. Sell-side analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be given a $1.24 dividend. The ex-dividend date is Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a yield of 3.40%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 29.68%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Recommended Stories
- Five stocks we like better than Johnson & Johnson
- Energy and Oil Stocks Explained
- Comprehensive PepsiCo Stock Analysis
- What does consumer price index measure?
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- The 3 Best Blue-Chip Stocks to Buy Now
- 3 Steel Stocks Could Soar on New China Tariffs
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.